Prima Biomed in trading halt
Prima Biomed shares halted pending announcement of oral vaccine for cervical cancer.
- 17 November, 2009 14:55
- Comments 1
Cancer treatment specialist pharmceutical company, Prima Biomed (ASX:PRR), has requested a trading halt on its shares until November 19 pending an announcement regarding the development its oral vaccine for cervical cancer.
Prima Biomed's flagship product is CVac, which is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of ovarian cancer.
Prima Biomed has had a stellar year on the markets. It began the year around $0.005 and rose around 3,200% to its current price.
Prima Biomed shares were last trading at 16.5c.
Latest Stories
Community Comments
-
UniQuest brokers international biofuel partnership
-
Apollo develops needle-free topical vaccine
-
Study reveals link between tea and rheumatoid arthritis
-
Halcygen (ASX:HGN) to expand board following departure of director and COO
-
AstraZeneca invests in Victoria's NeuProtect
Books
-
Fluorescence Applications in Biotechnology and Life Sciences
-
Molecular & Cell Biology for Dummies
-
Writing Scientific Research Articles - Strategy and Steps
-
Introduction to Statistics for Forensic Scientists
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
Dictionary of DNA and Genome Technology 2E
-
The Scientific American a Day in the Life of Your Brain
-
Statistics for Terrified Biologists
-
Proteins - Structure and Function
Get exclusive access to ALS, invitation only events, reports & analysis. 
Comments
gressuppy
dobry start
Post new comment